Search results for " denosumab"

showing 10 items of 25 documents

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized t…

2019

Highlights • Hormonal receptors positive breast tumor and prostate cancer are managed with endocrine therapies. • Endocrine therapies designed for breast and prostate cancer are often associated to serious adverse skeletal related events, such fractures. • Denosumab is a monoclonal anti-body binding RANKL which acts as inhibitor of osteoclasts activity, thus increasing bone mass. • Denosumab was showed to strongly prevent hormonal therapies-related skeletal issues. • Denosumab administration results safe in bone mass increase and reduction of fractures risk.

0301 basic medicineOncologyRCTs randomized clinical trialrandomized clinical trialslcsh:Diseases of the musculoskeletal systemSettore MED/06 - Oncologia MedicaOsteoporosisBMD bone mass densityReview Articleandrogen deprivation therapyADTlaw.inventionAndrogen deprivation therapyProstate cancerhazard ratio0302 clinical medicineRandomized controlled triallawHRMedicineBreastSAEsCancerProstateRANKLCIMD mean differencelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRCTs randomized clinical trialsDenosumabOncology030220 oncology & carcinogenesisSAEs serious adverse eventsDenosumabmean differencemedicine.drugmedicine.medical_specialtylcsh:RC254-28203 medical and health sciencesBreast cancerRANKL receptor activator of nuclear factor-kB ligandBMDInternal medicineAdverse effectADT androgen deprivation therapyRCTsbusiness.industryMDmedicine.diseaseHR hazard ratioHormonereceptor activator of nuclear factor-kB ligandDiscontinuationCI confidence interval030104 developmental biologyFractureconfidence intervalADT androgen deprivation therapy; BMD bone mass density; Breast; CI confidence interval; Cancer; Denosumab; Fracture; HR hazard ratio; Hormone; MD mean difference; Prostate; RANKL receptor activator of nuclear factor-kB ligand; RCTs randomized clinical trials; SAEs serious adverse eventsserious adverse eventsbone mass densitylcsh:RC925-935businessJournal of Bone Oncology
researchProduct

Osteonecrosis of the jaw after long-term oral bisphosphonates, followed by short-term denosumab treatment for osteoporosis: a case report

2014

Bisphosphonates and denosumab are antiresoptive agents and are mainly used for management of metastatic bone cancer, osteoporosis and other diseases. Bisphosphonates (BP) can reduce skeletal related events (SRE) by 30–50%1; denosumab (D) has been found even more effective than BP2. BP and D have been both associated to osteonecrosis of the jaw (ONJ). We report a case of an osteoporotic woman (62 yrs), complaining maxillary intense pain after a recent tooth molar extraction, observed in July 2013 at our centre. She mentioned previous treatments with monthly ibandronate (Bonviva ® 150 mg) per os (from January 2003 to April 2010), risedronate (35 mg weekly, from May 2010 to May 2012) and two a…

AbstractsOsteonecrosis jaw bisphosphonates denosumab osteoporosis
researchProduct

Osteonecrosi dei mascellari associata a bisfosfonati, denosumab e farmaci anti-angiogenetici nei pazienti oncologici e osteoporotici: diagnosi e tera…

2013

Riassunto Obiettivi Fornire un percorso utile alla diagnosi e al trattamento dell’osteonecrosi delle ossa mascellari (solitamente definita ONJ, OsteoNecrosis of the Jaws). Materiali e metodi Gli autori del lavoro, recentemente estensori e collaboratori – su mandato della Societa Italiana di Chirurgia Maxillo-Facciale (SICMF) e della Societa Italiana di Patologia e Medicina Orale (SIPMO), delle Raccomandazioni clinico-terapeutiche sull’osteonecrosi delle ossa mascellari associata a bisfosfonati e sua prevenzione – hanno esaminato le informazioni scientifiche disponibili in merito alla ONJ associata all’assunzione sia di bisfosfonati sia di denosumab e/o anti-angiogenetici, e revisionato l’ep…

Bisfosfonatibusiness.industryOsteonecrosi dei mascellariAnti-angiogeneticiMedicineOrthodonticsOral SurgeryDenosumabbusinessHumanitiesOsteonecrosi dei mascellari; Bisfosfonati; Anti-angiogenetici; DenosumabOsteonecrosi dei mascellari terapia
researchProduct

Osteonecrosi dei mascellari associata a bisfosfonati, denosumab e farmaci anti-angiogenetici nei pazienti oncologici e osteoporotici: prevenzione den…

2013

Riassunto Obiettivi Proporre protocolli di gestione odontoiatrica per il paziente che assume o che assumera farmaci (per esempio bisfosfonati, denosumab e anti-angiogenetici) correlati all’insorgenza di osteonecrosi dei mascellari (OsteoNecrosis of the Jaws, ONJ). Materiali e metodi Gli autori del lavoro, recentemente estensori e collaboratori – su mandato della Societa Italiana di Chirurgia Maxillo-Facciale (SICMF) e della Societa Italiana di Patologia e Medicina Orale (SIPMO), delle Raccomandazioni clinicoterapeutiche sull’osteonecrosi delle ossa mascellari associata a bisfosfonati e sua prevenzione – hanno esaminato le informazioni scientifiche disponibili in merito alla ONJ (associata a…

Bisfosfonatibusiness.industryOsteonecrosiAnti-angiogeneticiMedicineOrthodonticsDenosumabOral SurgerybusinessHumanitiesOsteonecrosi; Bisfosfonati; Anti-angiogenetici; DenosumabDental Cadmos
researchProduct

One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evalu…

2022

Antiresorptive drugs (bisphosphonates and denosumab) have become the cornerstone of medical supportive treatment of bone metastases in solid cancer patients. In the beginning, the choice of available antiresorptive agents was limited to bisphosphonates and the treatment options restricted principally to monthly pamidronate and monthly zoledronic acid. Introduction of new antiresorptive therapies (monthly denosumab) and schedules (zoledronic acid every 3 months, upfront or after initial period of monthly infusion) in the last decade increased the range of available options, thus challenging treatment decision making. Direct and indirect costs of very different treatment options are difficult…

Bone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawZoledronic acid; Denosumab; Bone metastases; Solid cancer; Osteonecrosis of the jaw; MRONJCost-Benefit AnalysisBone metastasesSolid cancerPamidronateBone NeoplasmsMRONJRisk AssessmentOncologyQuality of LifeHumansBisphosphonate-Associated Osteonecrosis of the JawDenosumabZoledronic acid
researchProduct

2020 Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis …

2020

Breast Cancer Denosumab Fracture HormoneProstate
researchProduct

Denosumab in patients with resectable giant cell tumor of bone (GCTB): Effect on surgical downstaging in a "real world" experience

2015

e21505 Background: Pre- surgical treatment with denosumab has been associated with downstaging in patients (pts) with resectable GCTB. Here, we report our “real world” experience with pre-operative...

Cancer Researchmedicine.medical_specialtybusiness.industryGiant Cell Tumor; DenosumabGiant Cell Tumormedicine.diseaseSurgeryDenosumabOncologyMedicineIn patientDenosumabbusinessSurgical treatmentGiant-cell tumor of bonemedicine.drug
researchProduct

Linfomi e salute dell'osso : è possibile migliorare la qualità di vita?

Linfoma osteoporosi DEXA denosumab bisfosfonati
researchProduct

Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: A Possible Role for RANK/RANKL Pathway

2017

AbstractSkeletal erosion has been found to represent an independent prognostic indicator in patients with advanced stages of chronic lymphocytic leukaemia (CLL). Whether this phenomenon also occurs in early CLL phases and its underlying mechanisms have yet to be fully elucidated. In this study, we prospectively enrolled 36 consecutive treatment-naïve patients to analyse skeletal structure and bone marrow distribution using a computational approach to PET/CT images. This evaluation was combined with the analysis of RANK/RANKL loop activation in the leukemic clone, given recent reports on its role in CLL progression. Bone erosion was particularly evident in long bone shafts, progressively inc…

Male0301 basic medicineChronic lymphocytic leukaemiaClone (cell biology)Osteoclastslcsh:MedicineMice0302 clinical medicineMice Inbred NODBone MarrowPositron Emission Tomography Computed Tomographyhemic and lymphatic diseases80 and overProspective StudiesChroniclcsh:ScienceAged 80 and overSettore ING-IND/24 - Principi Di Ingegneria ChimicaLeukemiaMultidisciplinaryBone Density Conservation AgentsReceptor Activator of Nuclear Factor-kappa BbiologyMiddle AgedLymphocyticLeukemiamedicine.anatomical_structureDenosumabRANKL030220 oncology & carcinogenesisFemaleDenosumabmedicine.drugAdultStromal cellArticle03 medical and health sciencesOsteoclastmedicineAnimalsHumansAgedRANK/RANKL Pathwaybusiness.industryRANK Ligandlcsh:RB-CellDiagnostic markersRANK LigandAdult; Aged; Aged 80 and over; Animals; Bone Density Conservation Agents; Bone Marrow; Denosumab; Female; Glucose; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Mice Inbred NOD; Middle Aged; Osteoclasts; Positron Emission Tomography Computed Tomography; Prospective Studies; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Xenograft Model Antitumor Assaysmedicine.diseaseLeukemia Lymphocytic Chronic B-CellXenograft Model Antitumor AssaysGlucose030104 developmental biologyChronic Lymphocytic Leukaemiabiology.proteinCancer researchInbred NODlcsh:QBone marrowbusiness
researchProduct

BRONJ in patients with rheumatoid arthritis: A multicenter case series

2016

Objective: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of various medications (bisphosphonates, anti-resorptive, and anti-angiogenic drugs). ONJ pathogenesis is still unclear although some risk factors have been recognized. Of these, rheumatoid arthritis (RA) has been hypothesized as a potential risk factor for developing ONJ. This observational study will describe a multicenter case series of patients affected with RA and ONJ, and it will attempt to evaluate the association between features of ONJ and pharmacological, systemic, and site variables. Methods: Demographic, pharmacological, and clinical data from 18 RA patients with ONJ were collected and registered fr…

Malemedicine.medical_specialtymedicine.medical_treatmentOsteoporosisONJArthritis Rheumatoid03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansBisphosphonateONJ; Bisphosphonate; Denosumab; Jaw; Osteonecrosis; Osteoporosis; Rheumatoid arthritis; Dentistry (all); Otorhinolaryngology2734 Pathology and Forensic MedicineRheumatoid arthritisAdverse effectGeneral DentistryRheumatoid arthritiAgedBisphosphonate-associated osteonecrosis of the jawbusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineOsteoporosiOsteonecrosis030206 dentistryBisphosphonateMiddle Agedmedicine.diseaseSurgeryDenosumabOtorhinolaryngologyJaw030220 oncology & carcinogenesisRheumatoid arthritisOsteonecrosiDentistry (all)OsteoporosisMethotrexateBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct